INTRODUCTION
============

*Helicobacter pylori* infection affects more than 50% of the world's human population and is associated with gastritis, peptic ulcer disease, and gastric cancer \[[@b1-kjim-2019-139]\]. In Korea, the *H. pylori* infection rate in adults is approximately 60% and gastric cancer is the second most frequently diagnosed malignancy \[[@b2-kjim-2019-139],[@b3-kjim-2019-139]\]. Successful eradication of *H. pylori* could be beneficial in alleviating *H. pylori*-related gastroduodenal diseases and reduce the risk of gastric cancer in countries like Korea where the prevalence of both *H. pylori* infection and gastric cancer are high. Until now, the triple therapy combining proton pump inhibitor (PPI) with two antibiotics (clarithromycin and amoxicillin) has been the standard first-line treatment for *H. pylori* eradication. Nonetheless, the eradication rate of this regimen has decreased to \< 80% \[[@b4-kjim-2019-139]-[@b7-kjim-2019-139]\].

The primary factor associated with eradication failure is clarithromycin resistance. In Korea, the clarithromycin resistance rate gradually increased from 17.2% to 23.7% during 2003 to 2008 \[[@b8-kjim-2019-139]\]. The second factor related to eradication failure is increased rates of antibiotic-associated adverse events, which could result in poor patient compliance \[[@b9-kjim-2019-139]\]. In areas with high clarithromycin resistance, bismuth-containing quadruple or non-bismuth quadruple therapies are recommended. Additionally, alternative treatment strategies that increase the eradication rate and reduce adverse events should be developed.

Probiotics supplementation with the standard triple therapy might be a candidate to satisfy this purpose. Administration of probiotics have reportedly improved *H. pylori* eradication rates and reduced adverse events associated with the triple therapy \[[@b10-kjim-2019-139]-[@b12-kjim-2019-139]\]. However, the inhibitory effect of probiotics on *H. pylori* infection remains controversial. Recently, two large meta-analyses showed that *Saccharomyces boulardii* reduced overall adverse events and increased eradication rates \[[@b13-kjim-2019-139]\]. Sulforaphane extracted from broccoli is another supplementary candidate for *H. pylori* eradication therapy. Broccoli sprout extract containing sulforaphane (BSES) exhibits cellular anti-oxidative, anti-inflammatory, and anti-cancer effects \[[@b14-kjim-2019-139]-[@b16-kjim-2019-139]\]. Sulforaphane is a potent bacteriostatic agent against *H. pylori* strains and also exhibits bactericidal effects in human epithelial cells \[[@b17-kjim-2019-139]\].

Although no statistically significant effects have been demonstrated in the previous study, we have identified a tendency to show positive results in some urea breath test (UBT) results; further studies have been presented on the effects of using the combination with standard triple therapy \[[@b18-kjim-2019-139]\]. This study excluded patients with cultures resistant to clarithromycin and registered only those subjects with infections not resistant to clarithromycin. Based on our literature review, to our knowledge, this is the first study designed to eliminate clarithromycin resistance as the affecting bias of *H. pylori* eradication failure. We aimed to determine whether *S. boulardii* probiotics or sulforaphane supplementation could increase the *H. pylori* eradication rate and/or reduce antibiotic-associated adverse events in a Korean population.

METHODS
=======

Patients and study protocol
---------------------------

All patients with *H. pylori*-positive chronic gastritis or peptic ulcer disease were recruited at the Kyung Hee University Hospital in Seoul, Korea, from August 2014 to April 2016. All participants were diagnosed with *H. pylori* infection using rapid urease or C^13^-UBTs. Patients with gastric cancer, previous gastrectomy, and severe underlying systemic diseases, or those who had received antibiotics or PPI within the previous month were excluded. Data including age, gender, cigarette smoking, alcohol intake, salty food consumption, family history of gastric cancer, body mass index (BMI), hypertension, and diabetes were collected. All patients underwent clarithromycin resistance testing and subjects with clarithromycin-resistant infections were excluded from the study. Finally, subjects were registered and a computer program was used to randomly assigned the subjects into three treatment groups: triple therapy only (group A), triple therapy plus probiotics (group B), and triple therapy plus sulforaphane (group C) ([Fig. 1](#f1-kjim-2019-139){ref-type="fig"}). Group A received 40 mg of pantoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 7 days. Groups B and C received the same PPI-based triple therapy for 7 days. Additionally, one capsule with either probiotics or sulforaphane was provided three times daily for 4 weeks to patients in groups B and C, respectively. All patients provided written informed consent prior to enrolment. This study was approved by the Institutional Review Board of the Kyung Hee University Hospital (KMC IRB: 1427-01) and registered with ClinicalTrials. gov (NCT03220542). All authors had access to the study data and reviewed and approved the final manuscript.

Probiotics and broccoli sprout extract containing sulforaphane
--------------------------------------------------------------

*S. boulardii* capsules (3 × 10^10^ colony-forming units/g, Bioflor, Kuhnil Pharm., Seoul, Korea) were administered as the probiotic. BSES capsules containing 250 mg standardized broccoli sprout, yielding 1,000 μg of sulforaphane (Oregon Health, Phoenix, AZ, USA), were administered. The doses from broccoli and probiotics were determined to meet the doses presented in several studies, including previous studies of us \[[@b18-kjim-2019-139]\].

Assessment of *H. pylori* eradication and adverse events
--------------------------------------------------------

C^13^-UBTs were performed 4 weeks after the last dose of the study medication. One week after completing treatment, information on adverse events and compliance was collected from the outpatient department through telephone interviews. Compliance was considered satisfactory when patients had taken \> 85% of the study medications.

Clarithromycin resistance tests
-------------------------------

Mutation of the 23S rRNA results in increased antibiotic resistance \[[@b19-kjim-2019-139]\]. Clarithromycin resistance in *H. pylori* in the present study was determined by evaluating for the presence of the A2142G or A2143G mutations in 23S rRNA. *H. pylori* genomic DNA was extracted from two biopsy specimens from the antrum and body collected during endoscopy. The DNA was amplified using the Seeplex home-brew primer mix from the Seeplex ClaR-*H. pylori* polymerase chain reaction (PCR) kit (Seegene Inc., Seoul, Korea) that was developed using a dual-priming oligonucleotide system to detect the A2142G or A2143G mutations.

CYP2C19 genotyping
------------------

The genotyping of exons 4 and 5 in *CYP2C19* was conducted by PCR with restriction fragment length polymorphism (PCR-RFLP). The polymorphism of *CYP2C19* was detected as previously described \[[@b20-kjim-2019-139]\]. The patients were classified into three groups according to *CYP2C19* genotype: rapid metabolizers (RM) had exon 5, wildtype/exon 4, wild-type; intermediate metabolizers (IM) had exon 5, wild-type/exon 4, heterozygote or exon 5, heterozygote/exon 4, wild-type; and poor metabolizers (PM) had both mutated alleles.

Data analysis
-------------

Eradication was evaluated using intention-to-treat (ITT) and per-protocol (PP) analyses. Continuous variables are expressed as means ± standard deviation, and categorical variables as percentages. Student's *t* test, chi-square test, and two-factor analysis of variation (ANOVA) were used. PASW Statistics for Windows version 22.0 (IBM Co., Armonk, NY, USA) was used for all statistical analyses. All statistical tests were two-tailed and *p* values of \< 0.05 were assumed to indicate statistical significance.

RESULTS
=======

Baseline characteristics of the study population
------------------------------------------------

A total of 217 patients with *H. pylori*-positive chronic gastritis or peptic ulcer disease were recruited during study periods. Of these, 34 subjects with clarithromycin-resistant infections were excluded from the study. The rate of clarithromycin resistance in this study was 17.3% (34/217 cases). Two cases were dropped. Finally, 183 patients with clarithromycin-sensitive infections were randomly assigned the subjects into three treatment groups: group A (n = 61), B (n = 61), and C (n = 61). The clinical parameters such as age, gender, cigarette smoking, alcohol intake, family history of gastric cancer, salty food consumption, and BMI, were similar among the three groups. Endoscopic finding and *CYP2C19* genotype did not differ significantly between the three groups ([Table 1](#t1-kjim-2019-139){ref-type="table"}).

Eradication rates
-----------------

The eradication rates according to ITT and PP analyses were 85.2% and 89.6% in group A, respectively. ITT and PP analyses showed 81.9% and 89.2% eradication rates in group B and 86.8% and 96.3% in group C, respectively. The eradication rates according to ITT and PP analyses were not significantly different across the groups based on two-group comparison tests (ITT analysis: A vs. B, *p* = 0.744; A vs. C, *p* = 1.000) (PP analysis: A vs. B, *p* = 0.313; A vs. C, *p* = 0.273). The eradication rate in group C was slightly higher compared to group A. However, the difference between the two groups (A vs. C) was not statistically significant ([Table 2](#t2-kjim-2019-139){ref-type="table"}).

Adverse events
--------------

In order of frequency, the adverse events included taste disturbance, diarrhea, headache, epigastric pain, nausea, and urticaria. The frequency of overall adverse events in the three groups was not significantly different (A vs. B, *p* = 0.574; A vs. C, *p* = 1.000). The frequencies of gastrointestinal disturbances such as diarrhea, epigastric pain, and nausea were lower in group B compared to group A, but the difference was not statistically significant (*p* = 0.339) ([Table 3](#t3-kjim-2019-139){ref-type="table"}).

*CYP2C19* genotypes
-------------------

Analysis of *CYP2C19* genotypes revealed the RM genotype in 16.4%, 24.6%, and 21.3% of patients in groups A, B, and C, respectively. The frequency of the RM genotype did not differ significantly across the three groups as per the results of the multiple group comparison test (*p* = 0.532) ([Table 1](#t1-kjim-2019-139){ref-type="table"}).

DISCUSSION
==========

The Maastricht V/Florence Consensus Report stated that PPI-clarithromycin-amoxicillin triple therapy without prior susceptibility test should be reconsidered in regions with a clarithromycin resistance rate above 15% \[[@b21-kjim-2019-139]\]. Based on our literature review, ours is the first study to exclude patients resistant to clarithromycin, which minimized the most significant bias associated with eradication failure. In our study, 17.3% of the patient infections were clarithromycin-resistant. In another recent Korean study, the clarithromycin resistance rate was \> 20% \[[@b22-kjim-2019-139]\]. This difference may be attributable to different tests used for assessing clarithromycin resistance as well as our study including a large number of relatively heathy subjects. Nonetheless, considering that the clarithromycin resistance rate was \> 15%, alternative regimens are needed for first-line treatment in Korea. Bismuth quadruple (PPI, bismuth, tetracycline, and metronidazole) or concomitant non-bismuth quadruple (PPI, amoxicillin, clarithromycin, and metronidazole) therapies are recommended as first-line treatments \[[@b21-kjim-2019-139]\]. However, these therapies are associated with poor patient compliance and increased adverse events owing to antibiotic overdose. Although not highly evident, supplemental therapy with probiotics or sulforaphane could increase eradication rates and decrease antibiotic-associated adverse events.

A meta-analysis of 10 clinical trials on the efficacy of probiotics in *H. pylori* treatment showed that *Lactobacillus*-containing and *Bifidobacterium*-containing probiotic compound preparations increased the overall eradication rate and decreased the overall adverse events \[[@b23-kjim-2019-139]\]. However, another meta-analysis of 33 randomized controlled trials (RCTs) could confirm this finding for only four individual strains (*Lactobacillus acidophilus*, *L. casei*, *L. gasseri*, and *Bifidobacterium infantis*) \[[@b24-kjim-2019-139]\]. This study also performed sub-group analysis according to the effectiveness of eradication regimens. In that study, the less effective the antibiotic therapies, the more useful the probiotic supplementation was: for eradication rates \< 60%, the pooled risk ratio (RR) was 1.28 (1.12 to 1.45), for eradication rates of 60% to 69%, the pooled RR was 1.18 (1.10 to 1.27); for eradication rates of 70% to 79%, the pooled RR was (1.11; 1.06 to 1.17); and supplementation had no effect for eradication rates \> 80% (pooled RR, 1.01; 0.96 to 1.77). The authors also reported a significant difference between the probiotics supplement and triple therapy only groups in the overall incidence of side effects (RR, 0.735; 95% confidence interval, 0.598 to 0.902) \[[@b24-kjim-2019-139]\]. However, the result of side effects was only confirmed for non-blinded trials.

One double-blind RCT showed that *Bacillus clausii* significantly reduced gastrointestinal adverse events such as nausea, epigastric pain, and diarrhea but insignificantly increased eradication rates \[[@b25-kjim-2019-139]\]. Recently, a meta-analysis of 11 RCTs showed that *S. boulardii* significantly increased eradication rates but that the rates were still below the desired level of success \[[@b13-kjim-2019-139]\]. Probiotics reduce antibiotic-associated adverse events such as nausea, diarrhea, and abdominal pain, thus helping the completion of eradication therapy. Therefore, probiotics can improve the *H. pylori* eradication rate by reducing adverse events rather than by directly eradicating *H. pylori*. The proposed mechanism of probiotics is to counteract the harmful effects of antibiotics on gut microbiota. However, the opposite conclusions were drawn regarding side effects in three studies reporting no significant reduction in overall side effects with probiotics use \[[@b26-kjim-2019-139]-[@b28-kjim-2019-139]\].

Our study showed that probiotic supplementation did not significantly increase the eradication rate. This may be because of several factors. Firstly, the number of subjects was small. Secondly, the eradication rate was \> 80% and so likely did not contribute an additive advantage, similar to that reported by Dang et al. \[[@b24-kjim-2019-139]\]. Overall, the rate of adverse events was lower in the probiotics supplement group B (triple therapy plus probiotics group) compared to group A (standard triple therapy only group). However, the difference was not statistically significant.

Sulforaphane is a molecule within the isothiocyanate group of organosulfur compounds. It can be obtained from cruciferous vegetables such as broccoli, Brussels sprouts, and cabbages. Sulforaphane enhances the protection and repair of the gastric mucosa against oxidative stress *in vitro* and has been shown to have anti-inflammatory effects on *H. pylori*-infected gastric mucosae in mice and human subjects \[[@b29-kjim-2019-139]\]. Sulforaphane has a potent bacteriostatic and bactericidal component against *H. pylori* *in vitro* \[[@b17-kjim-2019-139]\]. Furthermore, it is highly effective against a large number of clinical isolates of *H. pylori*, which are highly resistant to conventional antibiotics \[[@b17-kjim-2019-139]\]. Recently, sulforaphane was reported to reduce colonization and attenuate gastritis in *H. pylori*-infected mice and humans \[[@b30-kjim-2019-139]\]. However, a Japanese epidemiological investigation of the relationship between the prevalence of *H. pylori*-induced chronic atrophic gastritis (CAG) and broccoli consumption found no association between frequent broccoli consumption and a low prevalence of CAG. In addition, our previous study did not show the inhibitory effect of sulforaphane on *H. pylori* colonization density in the gastric mucosa of patients with *H. pylori*-positive gastritis \[[@b18-kjim-2019-139]\].

In the present study, the eradication rate in the sulforaphane supplementation group was slightly higher than that in group A (standard triple therapy only group), but the difference was not statistically significant. The overall rate of adverse events was also similar to group A.

Our study has some limitations. First, we included relatively small number of subjects in each group. However, this study was a single center study, and it had limitation to recruit enough patients during study period. Instead, during the study period, all patients who agreed to participate were enrolled by our study. In our study, probiotic supplementation and sulforaphane did not significantly increase the eradication rate nor decrease the adverse events. Nevertheless, the eradication rate in sulforaphane group was slightly higher than that in only triple therapy group. A further study including large number of subjects is needed in the future. Second, we used only *S. boulardii* capsules as the probiotic. The probiotics most commonly used include *Lactobacillus spp*., *Bacillus spp*., and yeast such as *S. boulardii*. The choice of the *S. boulardii* was determined by the effectiveness as well as being the most commonly used in most studies.

In conclusion, we found that supplement therapy with probiotics or sulforaphane for *H. pylori* eradication was ineffective at increasing eradication rates and decreasing adverse events.

KEY MESSAGE
===========

1\. Probiotic or sulforaphane supplementation with triple therapy for *Helicobacter pylori* infection did not significantly increase the eradication rate nor reduced the adverse events.

2\. An appropriate treatment strategy and new drawn up guidelines on treatment of *H. pylori* are necessary for the effective and safety eradication of *H. pylori*.
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###### 

Baseline characteristics of the study population

  Variable                 Group A (n = 61)   Group B (n = 61)   Group C (n = 61)   *p* value
  ------------------------ ------------------ ------------------ ------------------ -----------
  Age, yr                  53.20 ± 10.97      55.6 ± 10.65       55.77 ± 10.05      0.315
  Sex, male/female         33/28              30/31              30/31              0.821
  Smoking habits           14 (23.0)          13 (21.3)          10 (16.4)          0.644
  Alcohol intake           28 (45.9)          23 (37.7)          19 (31.1)          0.244
  Family history of GC     6 (9.8)            8 (13.1)           7 (11.5)           0.851
  Salty food consumption   16 (26.2)          27 (44.3)          26 (42.6)          0.076
  BMI                      24.10 ± 3.56       23.75 ± 2.47       23.77 ± 2.94       0.756
  Endoscopic findings                                                               
   Gastric ulcer           3 (4.9)            5 (8.2)            4 (6.6)            0.765
   Atrophy                 35 (57.4)          32 (52.5)          36 (59.0)          0.749
   Intestinal metaplasia   12 (19.7)          12 (19.7)          15 (24.6)          0.746
  *CYP2C19* genotype                                                                
   RM                      10 (16.4)          15 (24.6)          13 (21.3)          0.532
   IM                      44 (72.1)          40 (65.6)          44 (72.1)          0.660
   PM                      7 (11.5)           6 (9.8)            4 (6.6)            0.635

Values are presented as mean ± SD or number (%).

GC, gastric cancer; BMI, body mass index; RM, rapid metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.

###### 

*Helicobacter pylori* eradication rates among the three treatment groups

  Variable          Eradication rate   *p* value^[a](#tfn1-kjim-2019-139){ref-type="table-fn"}^   *p* value^[b](#tfn2-kjim-2019-139){ref-type="table-fn"}^           
  ----------------- ------------------ ---------------------------------------------------------- ---------------------------------------------------------- ------- -------
  Eradicated        52                 50                                                         53                                                                 
  Failed            6                  6                                                          2                                                                  
  Follow-up loss    1                  5                                                          6                                                                  
  Dropped out       2                  0                                                          0                                                                  
  Poor compliance   0                  0                                                          0                                                                  
  ITT analysis      52/61 (85.2)       50/61 (81.9)                                               53/61 (86.8)                                               0.744   1.000
  PP analysis       52/58 (89.6)       50/56 (89.2)                                               53/55 (96.3)                                               0.313   0.273

Values are presented as number (%).

ITT, intention to treat; PP, per protocol.

*p* was determined by two-group (A vs. B) comparison test.

*p* was determined by two-group (A vs. C) comparison test.

###### 

Adverse events in the three treatment groups

  Variable                                                        Group A (n = 61)   Group B (n = 61)   Group C (n = 61)   *p* value^[a](#tfn3-kjim-2019-139){ref-type="table-fn"}^   *p* value^[b](#tfn4-kjim-2019-139){ref-type="table-fn"}^
  --------------------------------------------------------------- ------------------ ------------------ ------------------ ---------------------------------------------------------- ----------------------------------------------------------
  Taste disturbance                                               30                 29                 28                 1.000                                                      1.000
  Diarrhea                                                        9                  5                  8                  0.396                                                      1.000
  Headache                                                        5                  2                  6                  0.440                                                      0.758
  Epigastric pain                                                 4                  3                  3                  1.000                                                      1.000
  Nausea                                                          3                  2                  1                  1.000                                                      0.619
  Urticaria                                                       3                  1                  1                  0.619                                                      0.619
  GI disturbance^[c](#tfn5-kjim-2019-139){ref-type="table-fn"}^   13                 8                  12                 0.339                                                      0.482
  Total                                                           36                 31                 34                 0.574                                                      1.000

GI, gastrointestinal.

*p* was determined by two-group (A vs. B) comparison test.

*p* was determined by two-group (A vs. C) comparison test.

Diarrhea, epigastric pain, and nausea.
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